EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Leveraging homologous recombination deficiency for sarcoma

Lara Planas-Paz, Chantal Pauli

Die Pathologie · 2024

DOI: 10.1007/s00292-024-01381-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Die Pathologie, 2024. Verfasst von Lara Planas-Paz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Sarcoma, Recombinational DNA Repair, Bone Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Zurich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Homologous recombination deficiency (HRD) in tumors correlates with poor prognosis and metastases development. Determining HRD is of major clinical relevance as it can be treated with PARP inhibitors (PARPi). HRD remains poorly investigated in sarcoma, a rare and heterogeneous cancer of mesenchymal origin.

Objective

We aimed (i) to investigate predictive biomarkers of HRD in several independent sarcoma cohorts using a cross-functional strategy by combining genomic, transcriptomic and phenotypic approaches and (ii) to evaluate the therapeutic potential of PARPi and DNA damage response (DDR)-based therapies ex vivo . Materials and methods We performed a comprehensive genomic and transcriptomic characterization of sarcoma using datasets from The Cancer Genome Atlas (TCGA) and Therapeutically Applicable Research to Generate Effective Treatments (TARGET), and our own bone and soft tissue sarcoma cohorts. We evaluated PARP1/2 and WEE1 inhibition ex vivo in patient-derived sarcoma cell models as monotherapy and in combination with chemotherapeutic agents to identify synergistic effects.

Results

Firstly, we identified genomic traits of HRD in a subset of sarcomas associated with molecular alterations in homologous recombination repair (HRR) pathway genes and high chromosomal instability. Secondly, we identified and validated distinct SARC-HRD transcriptional signatures that predicted sensitivity to PARPi. Finally, we showed functional defects in HRR in sarcoma cells that were associated with functional dependency towards PARPi and WEE1i and support the clinical use of RAD51 as a predictive biomarker for PARPi sensitivity.

Conclusion

We provide a personalized oncological approach to potentially improve the treatment of sarcoma patients. We encourage the evaluation of gene expression signatures to enhance the identification of patients who might benefit from DDR-based therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaRecombinational DNA RepairBone NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsHumansSoft Tissue NeoplasmsHomologous RecombinationCell Line, TumorOsteosarcoma

Stichwörter der Autor:innen

Cancer organoidsCombination therapyDNA damage responsePARPiPrecision oncology

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland. chantal.pauli@usz.ch.
  • Medical Faculty University of Zurich, Zurich, Switzerland. chantal.pauli@usz.ch.

Förderung

  • University of Zurich

Zitieren

APA

Planas-Paz, L., & Pauli, C. (2024). Leveraging homologous recombination deficiency for sarcoma. Die Pathologie. https://doi.org/10.1007/s00292-024-01381-y

Vancouver

Planas-Paz L, Pauli C. Leveraging homologous recombination deficiency for sarcoma. Die Pathologie. 2024. doi:10.1007/s00292-024-01381-y

BibTeX
@article{PlanasPaz2024,
  author = {Planas-Paz, Lara and Pauli, Chantal},
  title = {Leveraging homologous recombination deficiency for sarcoma},
  journal = {Die Pathologie},
  year = {2024},
  doi = {10.1007/s00292-024-01381-y}
}
Kostenlos starten →